Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy [5]

Chest

Volumn 118, Issue 6, 2000, Pages 1839-1840

  Waterer, G W ^a   Wunderink, R G ^a  

^a Pulmonary Host Defense Fellow   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; LEVOFLOXACIN; MACROLIDE; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; BACTEREMIA; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; LABORATORY DIAGNOSIS; LETTER; LOBAR PNEUMONIA; MINIMUM INHIBITORY CONCENTRATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

EID: 0034547104     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.118.6.1839-a     Document Type: Article

References (5)

1. A prediction rule to identify low-risk patients with community-acquired pneumonia
2. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
3. Community-acquired pneumonia in adults: Guidelines for management. The Infectious Diseases Society of America
4. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: A prospective randomized, multicenter trial
5. Pneumococcal macrolide resistance: Myth or reality?